Vertex has backed out of its in vivo gene editing collaboration with Verve Therapeutics before reaching the clinic. Verve, which attributed Vertex’s action to its changing R&D priorities, is ...
KING OF PRUSSIA, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today announced ...
The end of the Vertex-Verve collaboration comes as investors are reevaluating once sky-high expectations for the gene editing industry as commercial realities set in. Shares of Verve and top companies ...
Este formato para el flujo de caja está incluido en el [Pack de Formatos] 30 formatos de análisis financiero en Excel. Si ya tienes este producto, no es necesario que lo adquieras. El formato de flujo ...
Data supplied by Morningstar and accurate on Sep 30, 2024. It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback